Highlands Oncology Group — Springdale, Arkansas

Public research footprint of Highlands Oncology Group, compiled from the ClinicalTrials.gov public registry.

167

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Non-Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung · Muscle Invasive Bladder Urothelial Carcinoma · Glioma

Recently updated registry entries

NCT07061977 — Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation… (Recruiting)
NCT04728893 — Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic… (Recruiting)
NCT06662786 — A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Highlands Oncology Group?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.